Investigating the role of sulfatide in pancreatic cancer precursor lesions
Deregulation of Sulfatide Synthesis in the Development and Progression of Pancreatic Cancer Precursor Lesions
This study is looking at how a fat called sulfatide might play a role in the early stages of pancreatic cancer, and it aims to find out if changing how the body processes sulfatide can help stop cancer from growing, which could lead to better treatments for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-11102090 on NIH RePORTER |
What this research studies
This research focuses on understanding how sulfatide, a type of lipid, contributes to the development of pancreatic cancer precursor lesions, specifically intraductal papillary mucinous neoplasms (IPMN). Researchers will use advanced imaging techniques to analyze tissue samples from patients and mouse models to identify changes in sulfatide levels. The study aims to explore whether targeting sulfatide metabolism with small molecules can inhibit cancer growth and improve treatment outcomes. By examining these mechanisms, the research seeks to develop new strategies for early cancer interception.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with pancreatic cancer precursor lesions, particularly those with IPMN.
Not a fit: Patients with advanced pancreatic cancer or those without any precursor lesions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new methods for early detection and treatment of pancreatic cancer, potentially improving survival rates.
How similar studies have performed: Previous research has shown promise in targeting metabolic pathways in cancer treatment, suggesting that this approach could yield significant insights.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Fahrmann, Johannes F — University of Tx Md Anderson Can Ctr
- Study coordinator: Fahrmann, Johannes F
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.